Literature DB >> 14755390

Parametric randomization-based methods for correcting for treatment changes in the assessment of the causal effect of treatment.

A Sarah Walker1, Ian R White, Abdel G Babiker.   

Abstract

We develop parametric maximum likelihood methods to adjust for treatment changes during follow-up in order to assess the causal effect of treatment in clinical trials with time-to-event outcomes. The accelerated failure time model of Robins and Tsiatis relates each observed event time to the underlying event time that would have been observed if the control treatment had been given throughout the trial. We introduce a bivariate parametric frailty model for time to treatment change and time to trial endpoint. Estimating equations which respect the randomization are constructed and compared to maximum likelihood methods in a simulation study. The Concorde trial of immediate versus deferred zidovudine in HIV infection is used as a motivating example and illustration of the methods. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14755390     DOI: 10.1002/sim.1618

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  Methods for adjusting for bias due to crossover in oncology trials.

Authors:  K Jack Ishak; Irina Proskorovsky; Beata Korytowsky; Rickard Sandin; Sandrine Faivre; Juan Valle
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

2.  Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.

Authors:  James P Morden; Paul C Lambert; Nicholas Latimer; Keith R Abrams; Allan J Wailoo
Journal:  BMC Med Res Methodol       Date:  2011-01-11       Impact factor: 4.615

3.  Estimating causal effects using prior information on nontrial treatments.

Authors:  Simon J Bond; Ian R White
Journal:  Clin Trials       Date:  2010-09-03       Impact factor: 2.486

4.  Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.

Authors:  Nicholas R Latimer; Helen Bell; Keith R Abrams; Mayur M Amonkar; Michelle Casey
Journal:  Cancer Med       Date:  2016-01-27       Impact factor: 4.452

5.  Estimating efficacy in trials with selective crossover.

Authors:  Adam R Brentnall; Peter Sasieni; Jack Cuzick
Journal:  Stat Med       Date:  2017-03-15       Impact factor: 2.373

6.  Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.

Authors:  N R Latimer; K R Abrams; U Siebert
Journal:  BMC Med Res Methodol       Date:  2019-03-29       Impact factor: 4.615

7.  Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?

Authors:  N R Latimer; I R White; K R Abrams; U Siebert
Journal:  Stat Methods Med Res       Date:  2018-06-25       Impact factor: 3.021

8.  Diabetes, glucose control, glucose lowering medications, and cancer risk: a 10-year population-based historical cohort.

Authors:  Rachel Dankner; Ran Balicer; Paolo Boffetta; Lital Keinan Boker; Sylvan Wallenstein; Laurence Freedman; Margalit Goldfracht; Jesse Roth; Ronald Tamler; Derek LeRoith
Journal:  BMC Cancer       Date:  2012-08-23       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.